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Summary: Two column liquid Chromatographie (HPLC) methods for thexietermination of ciprofloxacin and
three metabolites are described. Both use reversed phase chromatography, the stationary phase being Nucleosil
5C18. Method A separates ciprofloxacin, metabolite Ml and another metabolite of unknown structure using
fluorometric detection. Method B allows the determinations of metabolite M3 (oxo-ciprofloxacin) in urine
by UV absorption. Serum was deproteinised with acetonitrile. Urine was diluted with buffer solution. The
detection limit of ciprofloxacin was 0.010 mg/1 serum and 0.2 mg/1 urine and for the metabolite M3, l mg/1
urine. Within-batch precision (coefficient of Variation) for ciprofloxacin in serum was 0.8 to 2.4% and
between-batch precision 4.8 to 9.3%. In urine within-batch precision was 1.7 to 2.1% and between-batch
precision 2.4 to 7.2%. Recovery rates of ciprofloxacin from three groups of spiked sera was 94.5 ± 2.6%,
97.2 + 1.1% and 95.0 ± 1.8% and from urine 99.6%. Results obtained by HPLC (method A) were compared
with those from a Standard microbiological assay by means of bivariäte regression analysis. In 12 subsets of
data the slope of the regression line varied from 1.042 to 1.556. Significantly higher results from the
microbiological assay were probably due to the presence of microbiologically active metabolites. We conclude
that HPLC is the more specific method of determination. The described methods were applied for pharmacoki-
netic studies and therapeutic drug monitoring.
Flüssigkeitschromatographische Bestimmung von Ciprofloxacin in menschlichen Körperflüssigkeiten
Zusammenfassung: Es werden zwei säulenchromatographische Methoden (HPLC) zur Bestimmung von
Ciprofloxacin und von drei Metaboliten beschrieben. Beide Methoden arbeiten nach dem Prinzip der reversed
phase Chromatography. Die stationäre Phase ist Nucleosil 5C18. Methode A trennt Ciprofloxacin, Metabolit
Ml und einen weiteren Metaboliten von bisher unbekannter Struktur und verwendet die Fluoreszenz zur
Detektiön. Methode B erlaubt die Bestimmung von Metabolit M3 (Oxo-ciprofloxacin) im Urin durch
UV-Absorption. Serum wurde mit Acetonitril enteiweißt. Urin wurde mit Pufferlösung verdünnt. Die
Nachweisgrenze von Ciprofloxaciii war 0,01 mg/1 Serum und 0,2 mg/1 Urin. Die Nachweisgrenze von
Metabolit M3 im Urin betrug l mg/1. Die Präzision in Serie, ausgedrückt als Variationskoeflfizient, betrug
für Ciprofloxacin im Serum 0,8 bis 2,4% und die Präzision von Tag zu Tag 4,8 bis 9,3%. Im Urin war die
Präzision in Serie 1,7 bis 2,1% und die Präzision von Tag zu Tag 2,4 bis 7,2%. Die Wiederauffmdung von
Ciprofloxacin aus Serum war in drei Serien 94,5 ± 2,6%, 97,2 ± 1,1% und 95,0 ± 1,8%. Die Wiederauffin-
dung aus Urin war 99,8%. Ergebnisse der HPLC-Methode A wurden mit den Ergebnissen eines üblichen
mikrobiologischen Assays mit der bivariaten Regressionsanalyse verglichen. In 12 Daten-Gruppen variierte
die Steigung der Regressionsgeraden von 1,042 bis 1,556. Die signifikant höheren Ergebnisse des Bioassays
wurden vermutlich durch das Vorliegen von mikrobiologisch aktiven Metaboliten verursacht. Die HPLC ist
unseres Erachtens die spezifischere Analysenmethode. Die beschriebenen HPLC-Methoden wurden zur
Auswertung phannakokinetischer Studien und im tfaerapeutic drug monitoring eingesetzt.
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Introduction
Ciprofloxacin (l -cyclopropyl-6-fluoro-l ,4-dihydro-4-
oxo-7-(l-piperazinyl-)-quinolone-3-carboxylic acid;
fig. 1) belongs to the recent derivatives of nalidixic
acid, called gyrase inhibitors. It has remarkable anti-
microbial activity (1 — 8) and is presently under clini-
cal evaluation. This paper describes the determination
of ciprofloxacin and three of its metabolites in human
body fluids. The method has been extensively used in












Reference material of ciprofloxacin (lot no. 907452, potency
842 mg/g) and of several metabolites (cf. fig. 1) were kindly
supplied by Bayer AG, Wuppertal, FRG. Tetrabutyl ammo-
nium phosphate (PIC A, low UV grade) was obtained from
Waters GmbH., Eschborn, FRG. Unless otherwise stated re-
agents and solvents were of reagent grade purity supplied by
E. Merck AG, Darmstadt, FRG. Redistilled water was used in
all experiments.
Volunteers and patients
Volunteers participating in pharmacokinetic studies were in-
structed not to take any drugs or caffeine- or quinine-contain-
ing beverages 24 h before and during the study. Patients were
on a regul r hospital diet and usually received 4 to 6 drugs
concomitantly which were recorded for ppssible analytical
interferences. All volunteers gave written informed consent
according to legal requirements in the FRG.
Blood was taken without additives and was allowed to clot at
room temperature. It was subsequently centrifuged at 3000 g
for 10 min. Serum and urine specimens for chromatography
were stored at -80°C for no more than 2 months before
processing. The microbiological determination was performed
on the day of sampling or on the day thereafter.
Preparation of the mobile phase
Solution of tetrabutyl ammonium phosphate: 5 mmol tetrabu-
tyl ammonium phosphate (l vial PIC A, Waters) were dissolved
in approximately 800 ml water. The solution was adjusted to
pH 2 with approximately 1.3 ml concentrated phosphoric acid
and made up to 11. , r
Method A
125 ml acetonitrile were mixed with tetrabutyl ammonium
phosphate solution and made up to a final Volume of l1.
Method B
220 ml acetonitrile were mixed with tetrabutyl ammonium
phosphate solution and made up to a final volume of 11.
The mobile phases were filtered before use and were recycled
for no mpre than 3 days of continuous Operation.
Preparation of Standards
A stock solution of 10 mg/1 ciprofloxacin was made by diluting
11.88 mg of reference material in water. The stock solution was
stable at 4 °C for at least l week. Working Standards (0.010 to
3.000 mg/1) were prepafed daily by dilution of the stock Stan-
dard with water. A Standard solution of metabolite M3 was
prepared by dissolving reference material in 0.5 ml 0.1 mol/1
sodium hydroxide and further dilution with 5 mmol/1 tetrabutyl
ammonium phosphate solution. Ml was dissolved in 0.1 rnol/1
hydrochloric acid.
Processing of samples
Urine was diluted with aqueous tetrabutyl ammonium
phate solution l : 40 to l: 10000 according to the expected
concentration. Serum was deproteinised by mixing 0.3 ml serum
with 0.6 ml acetonitrile. After centrifugation (2 min at 10 000 g)
0.3 ml superaatant was diluted with 1.2 ml aqueous tetrabutyl
ammonium phosphate solution. St ndard Solutions were
treated likewise. To measure the extraction rate 0.3 ml drug-
free serum was spiked with 0!l ϊηΐ Standard solution (0.400
mg/1) and processed s described bef fe. For control pf preci-
sion, serum and urine pools of vario s concentrations were
prepared from material obtained from volunteers.
High performance liquid chromatography (HPLC)
The Chromatograph consisted of the following modules: a pump
(flow rate l ml/min, pressure 15 MPa, m del 2/1, Perkin Eimer,
Uberlingen, FRG); an automatic sampler (injection volume 20
μϊ (urine) or 20 μΐ or 50 μΐ (serum), niodel LC 420, Perkin
Eimer); a precolumn (4 by 40 mm, Perisorb RP18, particle
diameter 30^40 μm, E. Merck); a reversed phase column
operated at room temperature 4 by 125 mm, Nuciepsil 5C18,
particle diameter 5 μηα, Macherey & Nagel, Puren); a flupres-
cence detector (excitation 275 nm, emission cut-off 418 nm,
time constant 4-6 s, model FS 970, Schoeffel GmbH,
Karlsruhe); and an integrator (model 3390A, Hewlett Packard,
Frankfurt). For method B a variable wavelength detector
(lambda 280 nm, model LC 85, Perkin Eimer) was used. C il··
centrations were calculated from peak areas. Serum results were
corrected for extraction rate. In sera from patients an extraction
ratio of 0.95 was assumed.
Microbiological assay of ciprofloxacin
A microbiplogical assay which served s comparison was pef^
formed with a Standard agar plate diffussion technique (12).
The test species was Klebsiella pneumoniae ATCC 10031 fpr
concentrations below 0.15 mg/1 and Bacillus subtilis ATCC-6633
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for concentrations above 0.15 mg/1. Samples and Standards
were assayed in triplicate. For qualitative detection of antimi-
crobial activity in Chromatographie fractions a commercial test
strip (Micur® BT, Boehringer Mannheim, FRG) was used.
Statistical calculations
Bivariate regression analysis was performed s previously de-
scribed (13).
Results
Development of the method
Ciprofloxacin showed a typical UV absorption spec-
trum with a maximum at 275 nrri. Upon excitation
at 275 nm an intense blue fluorescence was observed
with a maximum at 450 nm. For determination of
the parent compound and the metabolite Ml (cf. fig.
1) detection by fluorescence was used in method A.
The main metabolite M3, however, yielded a very
low fluorescence and it was therefore quantitated by
UV absorption in method B. The Separation principle
of both methods was reversed phase chromatography.
Typical chromatograms from serum and urine show
the Separation of ciprofloxacin and the metabolites
Ml and m2 from endogenous compounds by method
A (flg. 2 and fig. 3). Addition of tetrabutyl ammo-
nium phosphate to the mobile phase was essential
to avoid tailing of the peaks. Retention times of
fluorescent compounds encountered in monitoring
ciprofloxacin therapy of patients are given in table 1.
Only tyrosine eluted close to ciprofloxacin. However,
a high serum concentration of 100 μπιοΐ/ΐ tyrosine
produced a detector response equivalent to only
3 μg/l ciprofloxacin. For the elution of M3, the main
metabolite in urine, the concentration of acetonitrile
in the mobile phase had to be increased. Typical
chromatograms obtained by method B using UV
detection are shown in figure 4. Peaks of ciproflox-
acin and Ml were qualitatively identified in l ml
t [min] o s
Int er VQ l Standard
t C m i n D o s
Int er να l eo min
t min] o
Interval 4h
Fig. 2. Examples of chromatpgrams. Serum of a normal volunteer after a single oral dose of 750 mg ciprofloxacin. Separation
of ciproflox cin (C), Ml and m2 by method A.




Fig. 3. Examples of chromatograms. Urine of a normal volunteer after a intravenous oral dose of 100 mg ciprofloxacin.
Separation of ciprofloxacin (C), Ml and m2 by method A. t
t = retention time; the interval indicated below each chromatogram refers to sampling penod after intake of the drug;
Dilution = sample dilution.
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Tab. l. Retention times of ciprofloxacin and various fluores-

































Retention times are relative to ciprofloxacin.
fractions collected after chromatography by UV spec-
troscopy and by demonstration of antibacterial activ-
ity, and also by addition of pure substances to the
sample.
Precision and accuray
Within-batch precision was measured in two serum
pools, each in 10 replicates. Coefficients of Variation
were 0.8% (c = 1.45 mg/1) and 2.4% (c = 0.42 mg/1)
for the complete protocol. For additional results see
table 2. Between-bätch precision was also measured
in several serum and urine pools. Results are sum-
marised in table 3. For serum concentrations of cipro-
floxacin between 0.35 and 2.2 mg/1 coefficients of
Variation varied from 4.8 to 9.3% and for urine
samples coefficients of Variation were between 2.4
and 7.2%. The average recovery of ciprofloxacin
from 24 spiked drug-free sera was 94.5 ± 2.6% of
the added concentration (c = 1.875 mg/1). In another
two series of 12 and 9 sefa, the mean recoveries
were 97.2 ± 1.1% and 95.0 ± 1.8%. Recovery of
ciprofloxacin from spiked urine was 99.6%.
Linearity and sensitivity
Detection limits of ciprofloxacin by method A —
estimated from the smallest detectable area by the
integrator - were 10 g/l in serum and 200 g/l in
urine at the most sensitive setting of the fluorimeter.
Detector response measured by peak areas was lin-
early proportional to concentration over a ränge of
l to 100. For very low concentrations the injection
volume could be increased from 20 to 50 withput
distortion of the chromatogram. The detection limit
of M3 by method B was l mg/1 in urine.
Comparison of methods
In several hundred samples from healthy volunteers
concentrations of ciprofloxacin were determined both
by chromatography and a conventional microbiologU
cal assay. Results of bivariate regression analysis and
of the sign test of paired differences are summarised
in table 4. Examples of repräsentative däta sets are
shown in figures 5 and 6. With the exception of two
data sets obtained after a low dose (50 mg, urine) all
bioassay results were significantly higher than the
results obtained by chromatography.
v
M3




















V°lunteer after a single oral dose of 25° mg ciprofloxacin. Determination
t = retention time; the interval indicated below each ehroinatogram refers to sampling period after intake of the drug.
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Tab. 2. Within-batch precision of method A. Tab. 3. Between-batch precision of method A.



















































Concentrations of m2 are only given in fluorescence equivalents


































































Concentrations of m2 are only given in fluorescence equivalents
relative to ciprofloxacin (figures in brackets).




































































































0.2 0.4 0.6 0.8 1:0 1.2 U
Ciprof'loxacin, serum (HPLC) img/ll
fl.6 500 1000 1500
Ciprofloxacin, urine (HPLC) [mg/l]
Fig. 5. Comparison of methods. Ciprofloxacin in serum after Fig. 6. Comparison of methods. Ciprofloxacin in urine after a
a single intravenous dose of 50 mg. Bivariate regression single oral dose of 750 mg. Bivariate regression analysis:
analysis: y (bioassay) = 1.107x (HPLC) + 0.002 mg/i. y (bioassay) - 1.264X (HPLC) - 0.6 mg/1.
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Interferences
Up to now, ciprofloxacin has been determined in
more than 2000 samples, serum and urine, from
healthy volunteers without any interference. In
another study on 60 patients there was only one
unexplained analytical interference in a patient with
terminal renal insufficiency, who had received several
other drugs simultaneously.
Discussion
Ciprofloxacin is a very potent antimicrobial agent äs
compared with other groups of antibiotics (1—8).
E. g., MIC90 values of 0.015 to 2 mg/1 were reported
for several Gram-negative species (2). Thus, a fairly
sensitive method was required for its determination
in human body fluids. Furthermore it had to be taken
into accourit' that ciprofloxacin is partially meta-
bolised by the human organism (9, 10). Some of its
metabolites still showed activity in the microbiologi-
cal assay used. Metabolites can also interfere in Chro-
matographie methods. The chemical structures of
three metabolites have so far been identified (cf. fig.
1) (14). Another metabolite is at present under inves-
tigation by co-workers of the manufacturer. This
paper shows an additional possible metabolite called
m2 the structure of which is unknown at present (cf.
figs. 2 and 3). Metabolite M4 could not be detected
in urine. According to 1. c. (14) its renal excretion is
less than l % of the dose.
Method A uses fluorescence detection for high sensi-
tivity and better specificity. It differs from a method
first described by Gau (15) in the method of deprote-
inisation, the stationary phase and completeness of
Separation. During the preparation of the manuscript
similar Chromatographie methods for ciprofloxacin
have been published (16—18), none of which deals
with the quantitation of the metabolites. The present
method A separated ciprofloxacin from all known
metabolites (cf. figs. 2 and 3). It was sufficiently
sensitive to measure serum concentrations up to 24 h
after administration of a single oral dose of 250 mg.
Precision and recovery were satisfactory. Since the
quanturn yield of the metabolites differs considerably
from that of the parent compound, calibration of the
fluorescence detector with pure reference substances
is essential. The poor precision obtained with metab-
olite m2 in serum (tab. 2) was probably due to the
rather small signal relative to the parent compound
to which the fluorometric detector was adjusted (cf.
fig. 2).
Method B was developed for the main metabolite
M3 (oxo-ciprofloxacin), which yielded low fluores^
cence and was less polar (cf. fig. 4).
Results of the microbiological assay perfonned with
split samples were generally sornewhat higher than
results obtained by chromatography (tab. 4). The
differences were more pronounced in urine than in
serum. This is likely to be due to the presence of
metabolites with antimicrobial activity, the cöncen-
tration of which is usually higher in urine than in
serum. In one trial a single oral dose of 250 mg
ciprofloxacin was given to 10 volunteers. The mean
renal elimination within 24 h was ciprofloxacin 33.6
± 8.0% of the dose, metabolite Ml 1.3 ± 0.5% and
metabolite M3 5.5 ± 8.0% (11). Metabolite M3 had
an activity of 74% relative to ciprofloxacin. Similar
differences between microbiological and Chromato-
graphie results were reported for urine (16) and for
bile (18). For this reason liquid chromatography ap ·̂
pears the more spetific method for ciprofloxacin and
is recommended both for pharmacokinetic studies
and therapeutic drug monitoying. For the lätter appli-
cation some caution is warranted in patients on con-
comitant treatment with drugs that also fluoresce.
Since clinical experience with ciprofloxacin is pres-
ently still limited, indications for routine therapeutic
drug monitoring are not yet defmed. Possible indica-
tions might be high dose therapy in severe infections
and/or reduced elimination capacity in renal or he-
patic disease.
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